Canada Issues Regulations to Lower Patent Drug Prices

Health Canada has finalized regulations that knock the U.S. and Switzerland off its price comparator list and tighten disclosure requirements.

The agency claimed that the U.S. lacks policies that control free market pricing for medicines and axed the country from the list used by its drug pricing regulator, the Patented Medicine Prices Review Board.

The amended regulation requires patentholders to report the actual price they charge — including direct or indirect third-party discounts or rebates.